Dual-Targeting Biomimetic Nanozymes Loaded Microneedle Patch Promotes Scarless Wound Healing Through Anti-Inflammatory and Anti-Fibrotic Effects.

Authors

Hongyi Zhang, Jinwei Li, Shan Hua, Shengming Wu, Chenlong He, Yuan Zhu, Ming Yin, Han Zhou, Huawei Liu, Chika Hasegawa, Jun Lyu, Keyue Xiao, Hua Jiang, Yilong Wang, Yuxin Qian

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e77192. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

During skin wound healing, complex interactions among multiple cell types and dynamic phase evolution make it difficult for biomaterial scaffolds to balance late-healing and over-healing, often resulting in delayed wound healing, persistent inflammatory responses, and hypertrophic scars due to spatiotemporal mismatch. Precise regulation of fibroblast-to-myofibroblast transformation and macrophage polarization is therefore essential yet challenging. Fibroblast activation protein (FAP) has been identified as a key bio-cue in pulmonary and hepatic fibrosis, but whether FAP-targeting peptide (FTP) within a biomimetic system can address this dilemma remains unclear. Here, a methacrylated hyaluronic acid hydrogel microneedle patch (CAF@MN) integrating a dual-targeting biomimetic nanozyme system (Cu-CeO₂@ABs-FTP) modified with apoptotic bodies (ABs) membranes and FTP is developed. Cu-CeO₂ nanocomposites activate fibroblast functions and exhibit anti-inflammatory, antibacterial, antioxidant, and pro-angiogenic activities. The ABs membrane enables macrophage targeting and M2 polarization, while FTP specifically modulates myofibroblast activation. The microneedle architecture enhances deep local delivery and nanozyme utilization. In mouse and rabbit full-phase wound models, the system achieves accelerated wound healing, reduced inflammation, and attenuated hypertrophic scars. Single-cell RNA sequencing further elucidates the dual-targeted regulatory mechanisms underlying anti-inflammation and scar suppression.

PMID:
42606143
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.